Author: Mendroneâ€Junior, Alfredo; Dinardo, Carla Luana; Ferreira, Suzete Cleuza; Nishya, Anna; Salles, Nanci Alves; de Almeida Neto, Cesar; Hamasaki, Debora Toshei; Facincani, Tila; de Oliveira Alves, Lucas Bassolli; Machado, Rafael Rahal Guaragna; Araujo, Danielle Bastos; Durigon, Edison Luiz; Rocha, Vanderson; Sabino, Ester Cerdeira
Title: Correlation between SARSâ€COVâ€2 antibody screening by immunoassay and neutralizing antibody testing Cord-id: 9chgsnzj Document date: 2021_1_25
ID: 9chgsnzj
Snippet: BACKGROUND: The efficacy of convalescent plasma (CP), an alternative for the treatment of COVIDâ€19, depends on high titers of neutralizing antibodies (nAbs), but assays for quantifying nAbs are not widely available. Our goal was to develop a strategy to predict high titers of nAbs based on the results of antiâ€SARSâ€CoVâ€2 immunoassays and the clinical characteristics of CP donors. STUDY DESIGN AND METHODS: A total of 214 CP donors were enrolled and tested for the presence of antiâ€SARSâ€
Document: BACKGROUND: The efficacy of convalescent plasma (CP), an alternative for the treatment of COVIDâ€19, depends on high titers of neutralizing antibodies (nAbs), but assays for quantifying nAbs are not widely available. Our goal was to develop a strategy to predict high titers of nAbs based on the results of antiâ€SARSâ€CoVâ€2 immunoassays and the clinical characteristics of CP donors. STUDY DESIGN AND METHODS: A total of 214 CP donors were enrolled and tested for the presence of antiâ€SARSâ€CoVâ€2 antibodies (IgG) using two commercial immunoassays: EUROIMMUN (ELISA) and Abbott (Chemiluminescence). Quantification of nAbs was performed using the Cytopathic Effectâ€based Virus Neutralization test. Three criteria for identifying donors with nAbs ≥ 1:160 were tested: – C1: Curve ROC; − C2: Conditional decision tree considering only the IA results and – C3: Conditional decision tree including both the IA results and the clinical variables. RESULTS: The performance of the immunoassays was similar referring to both S/CO and predictive value for identifying nAbs titers ≥1:160. Regarding the studied criteria for identifying CP donors with high nAbs titers: (a) C1 showed 76.1% accuracy if S/CO = 4.65, (b) C2 presented 76.1% accuracy if S/CO ≥4.57 and (c) C3 had 71.6% accuracy if S/CO was ≥4.57 or if S/CO was between 2.68â€4.57 and the last COVIDâ€19â€related symptoms were recent (within 19 days). CONCLUSION: SARSâ€CoVâ€2 IgG immunoassays (S/CO) can be used to predict high antiâ€SARSâ€CoVâ€2 nAbs titers. This study has proposed different criteria for identifying donors with ≥1:160 nAbs titers, all with high efficacy.
Search related documents:
Co phrase search for related documents- action mechanism and acute viral infection: 1, 2, 3
- action mechanism and low mortality: 1
- acute viral infection and low mortality: 1
Co phrase search for related documents, hyperlinks ordered by date